Chong Kun Dang Pharmaceutical: Diabetes Mellitus, Type 2 trials

The registry lists 57 Diabetes Mellitus, Type 2 studies with Chong Kun Dang Pharmaceutical as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 46Phase 2 1Phase 3 6Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus PatientsNot yet recruitingNCT07365358Phase 4
• Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 DiabetesRecruitingNCT06838286
• To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy VolunteersNot yet recruitingNCT06492655Phase 1
• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersCompletedNCT07304726Phase 1
• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersCompletedNCT07304700Phase 1
• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersCompletedNCT07304687Phase 1
• Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy VolunteersCompletedNCT06709807Phase 1
• Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy VolunteersCompletedNCT06695598Phase 1
• Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy VolunteersCompletedNCT06695572Phase 1
• A Clinical Trial to Evaluate the Food Effect of CKD-379CompletedNCT06652971Phase 1
• Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.CompletedNCT06483243Phase 1
• A Clinical Trial to Evaluate the Food Effect of CKD-378CompletedNCT06386328Phase 1
• A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379CompletedNCT06204107Phase 1
• Study to Evaluate the Safety and Pharmacokinetics of CKD-379Active, not recruitingNCT05952219Phase 1
• A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150CompletedNCT05928637Phase 1
• Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy AdultsCompletedNCT05881213Phase 1
• A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378CompletedNCT05741437Phase 1
• Pharmacokinetics and Safety/Tolerability of CKD-379CompletedNCT05719155Phase 1
• The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 DiabetesCompletedNCT05566028Phase 3
• Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy SubjectsCompletedNCT05544214Phase 1
• Pharmacokinetics and Safety/Tolerability Profile of CKD-379CompletedNCT05452525Phase 1
• Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393CompletedNCT05274880Phase 1
• Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes MellitusCompletedNCT05043467
• Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mgCompletedNCT04869800Phase 1
• A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.CompletedNCT04810676Phase 1
• A Study to Investigate the PK and Safety of CKD-393CompletedNCT04768673Phase 1
• Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393Status unknownNCT04706286Phase 1
• A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)CompletedNCT04431687Phase 1
• Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy SubjectsCompletedNCT04260438Phase 1
• A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult VolunteersStatus unknownNCT04223895Phase 1
• A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375Status unknownNCT04221360Phase 1
• Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1CompletedNCT04156685Phase 1
• Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy AdultsStatus unknownNCT03849495Phase 1
• Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed ConditionStatus unknownNCT03849339Phase 1
• Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy AdultsStatus unknownNCT03849261Phase 1
• The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375Status unknownNCT03848637Phase 1
• Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesCompletedNCT03739125Phase 3
• The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed ConditionCompletedNCT03738449Phase 1
• Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy AdultsStatus unknownNCT03646799Phase 1
• The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 DiabetesStatus unknownNCT03641352Phase 3
• Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesStatus unknownNCT03627182Phase 3
• Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308CompletedNCT03616392Phase 1
• Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mgStatus unknownNCT03601910Phase 1
• Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownNCT02854748Phase 1
• CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)CompletedNCT02827890Phase 1
• CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)CompletedNCT02824874Phase 1
• A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male VolunteersCompletedNCT02685774Phase 1
• Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersCompletedNCT02648854Phase 1
• A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male VolunteersCompletedNCT02627027Phase 1
• A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male VolunteersCompletedNCT02565368Phase 1
• Efficacy and Safety of Lobeglitazone Versus SitagliptinStatus unknownNCT02480465Phase 4
• Drug-drug Interaction Study(Lobeglitazone, Warfarin)CompletedNCT02002611Phase 1
• Drug-drug Interaction Study(CKD-501, Amlodipine)CompletedNCT01341392Phase 1
• Drug-drug Interaction Study (CKD-501, Ketoconazole)CompletedNCT01330563Phase 1
• Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to MetforminCompletedNCT01106131Phase 3
• Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes MellitusCompletedNCT01030679Phase 2
• An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes MellitusCompletedNCT01001611Phase 3